PERSON
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
Zepbound, FDA approval, obstructive sleep apnea, obesity, tirzepatide, sleep disorder treatment
FDA Imposes Import Restrictions on 11 Viatris Products from Indian Facility Due to Regulatory Violations
Viatris, FDA, Import Restrictions, India Facility, Regulatory Violations, Pharmaceutical Manufacturing
Eli Lilly’s Zepbound Wins Historic FDA Approval for Treating Obstructive Sleep Apnea in Adults with Obesity
Zepbound, tirzepatide, FDA approval, obstructive sleep apnea, obesity, weight loss, sleep disorder treatment
Celebrating Visionaries: Insights from the 2024 Fierce 50 Honorees
Fierce 50, 2024 Honorees, Healthcare Innovation, Biopharma, Health Equity, Patient Advocacy
Javara Undergoes Restructuring, Lays Off Staff Amidst Industry-Wide Challenges
Javara, layoffs, restructuring, clinical research, biopharma industry challenges
Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations, Highlighting High Investor Expectations
CagriSema, Novo Nordisk, Weight Loss Drugs, REDEFINE 1 Trial, Obesity Treatment, Investor Expectations
Breakthrough in Familial Chylomicronemia Syndrome: FDA Approves Ionis’ Tryngolza as First Treatment
Familial Chylomicronemia Syndrome (FCS), Ionis Tryngolza, FDA Approval, Rare Genetic Hyperlipidemia, Acute Pancreatitis, Lipid-Lowering Therapy
CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target
CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide
Applied Therapeutics Undergoes Leadership Change Amid FDA Rejection and Investor Lawsuit
Applied Therapeutics, FDA rejection, investor lawsuit, leadership change, John H. Johnson, Les Funtleyder, Shoshana Shendelman
Bristol Myers Squibb Invests $100M in BioArctic for Next-Generation Alzheimer’s Therapies
Alzheimer’s disease, Bristol Myers Squibb, BioArctic, Leqembi, preclinical antibodies, BAN1503, BAN2803